Ultragenyx Pharmaceutical reported $73.83M in Gross Profit on Sales for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US $ 112.52M 15.68M
Alnylam Pharmaceuticals ALNY:US $ 177.63M 43.24M
Biocryst Pharmaceuticals BCRX:US $ 49.68M 2.95M
Biomarin Pharmaceutical BMRN:US $ 402.39M 72.33M
Epizyme EPZM:US $ 6.06M 2.37M
Esperion Therapeutics ESPR:US $ 11.71M 1.38M
Insmed INSM:US $ 40.92M 1.92M
IONIS PHARMACEUT IONS:US $ 137.75M 300.03M
Karyopharm Therapeutics KPTI:US $ 46.24M 79.28M
Kyowa Hakko Kirin 4151:JP Y 65592M 8944M
MacroGenics MGNX:US 11.05M 2.15M
Moderna Inc MRNA:US 5.05B 1.21B
Neurocrine Biosciences NBIX:US $ 306M 1.9M
Ptc Therapeutics PTCT:US $ 138.6M 17.3M
Puma Biotechnology PBYI:US $ 34.89M 8.57M
Regeneron Pharmaceuticals REGN:US $ 2560.2M 1408.9M
Sarepta Therapeutics SRPT:US $ 179.39M 9.67M
Ultragenyx Pharmaceutical RARE:US $ 73.83M 6.04M
Vertex Pharmaceuticals VRTX:US $ 1851.7M 26.53M